Pacific Edge (ASX:PEB) ROA %: -121.85% (As of Mar. 2026)


ASX:PEB Pacific Edge Ltd ASX:PEB
42 GF Score
Price A$0.25
GF Value A$0.05
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Pacific Edge ROA %?

Pacific Edge ASX:PEB -3.85% 42 ROA % is -121.85% as of Mar. 2026. GuruFocus rates ASX:PEB with a GF Score™ of 42/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Pacific Edge ranks worse than 92.09% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Pacific Edge's annualized Net Income for the quarter that ended in Mar. 2026 was A$-27.77 Mil. Pacific Edge's average Total Assets over the quarter that ended in Mar. 2026 was A$22.79 Mil. Therefore, Pacific Edge's annualized ROA % for the quarter that ended in Mar. 2026 was -121.85%.

The historical rank and industry rank for Pacific Edge's ROA % or its related term are showing as below:

ASX:PEB' s ROA % Range Over the Past 10 Years
Min: -130.98   Med: -62.26   Max: -23.92
Current: -120.2

During the past 13 years, Pacific Edge's highest ROA % was -23.92%. The lowest was -130.98%. And the median was -62.26%.

ASX:PEB's ROA % is ranked worse than
92.09% of 215 companies
in the Medical Diagnostics & Research industry
Industry Median: -1.87 vs ASX:PEB: -120.20

Pacific Edge  (ASX:PEB) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-27.77/22.79
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-27.77 / 9.266)*(9.266 / 22.79)
=Net Margin %*Asset Turnover
=-299.7 %*0.4066
=-121.85 %

Note: The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Pacific Edge ROA % Related Terms


Pacific Edge ROA % Historical Data

* Premium members only.

The historical data trend for Pacific Edge's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Edge ROA % Chart

Pacific Edge Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.96 -26.13 -37.72 -57.67 -123.39

Pacific Edge Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.43 -49.62 -69.80 -105.60 -121.85

ASX:PEB vs TMO, DHR, IDXX: ROA % Comparison

For the Diagnostics & Research subindustry, Pacific Edge's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Edge ROA % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's ROA % distribution charts can be found below:

* The bar in red indicates where Pacific Edge's ROA % falls into.


ASX:PEB
42GF Score
Pacific Edge Ltd ASX:PEB
ROA % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacific Edge ROA % Calculation

Pacific Edge's annualized ROA % for the fiscal year that ended in Mar. 2026 is calculated as:

ROA %=Net Income (A: Mar. 2026 )/( (Total Assets (A: Mar. 2025 )+Total Assets (A: Mar. 2026 ))/ count )
=-29.815/( (33.658+14.668)/ 2 )
=-29.815/24.163
=-123.39 %

Pacific Edge's annualized ROA % for the quarter that ended in Mar. 2026 is calculated as:

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-27.77/( (30.912+14.668)/ 2 )
=-27.77/22.79
=-121.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Mar. 2026) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -121.85% mean?
Pacific Edge (ASX:PEB) has a ROA % of -121.85% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Pacific Edge and its competitors. According to the industry distribution chart, Pacific Edge ranks #198 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 92.1%.
Is Pacific Edge's ROA % too high?
Pacific Edge's current ROA % is -121.85%. Based on the distribution chart, Pacific Edge ranks #198 out of 215 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pacific Edge has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's ROA % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pacific Edge ranks #198 out of 215 companies for ROA %. This places Pacific Edge in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Pacific Edge and its competitors. Pacific Edge's current ROA % is -121.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.25 — trading 400% above its estimated fair value. The current ROA % is -121.85%. Pacific Edge's overall GF Score™ is 42/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current ROA % is -121.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Edge (ASX:PEB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued. The current stock price of A$0.25 is trading 400% above its estimated GF Value™ of A$0.05. GuruFocus considers Pacific Edge to be Significantly Overvalued.

Key valuation signals for ASX:PEB:

  • ROA %: -121.85%
  • GF Value™: A$0.05 vs. price of A$0.25 (400% above fair value)
  • GF Score™: 42/100 with 8 warning signs

No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacific Edge Business Description

Address 87 Saint David Street, P.O. Box 56, Dunedin, STL, NZL, 9016
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
42GF Score

Get the complete analysis for ASX:PEB

ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.25
Price
A$0.05
GF Value